Sign up USA
Proactive Investors - Run By Investors For Investors

Valeant Pharmaceuticals International Inc misses hopes and drops FY guidance

Shares in the company plummeted more than 25% in early deals to $50.50.
Valeant Pharmaceuticals International Inc misses hopes and drops FY guidance
The firm blamed the weak performance on slowdowns in the US dermatology, gastrointestinal and woman's health businesses.

Beleaguered Canadian drugs maker Valeant Pharmaceuticals International Inc (TSE:VRX, NYSE:VRX) heaped more misery on investors on Tuesday as figures from its latest quarter missed expectations and it cut its revenue forecast for the year.

The company posted fourth-quarter adjusted earnings per share of $2.50, compared to $2.58 a share in the same period the year before, while revenue for the quarter was around $2.79bn.

Analysts had expected the company to report earnings of $2.61 per share with revenue of around $2.75bn, according to reports.

The firm blamed the weak performance on slowdowns in the US dermatology, gastrointestinal and woman's health businesses.

Valeant also reduced its first-quarter and full-year outlook, expecting first-quarter earnings of $1.30 to $1.55 a share, on revenue of $2.3bn to $2.4bn and earnings of $9.50 to $10.50 a share for the year on revenue of between $11bn and $11.2bn.

Shares in the company plummeted more than 25% in early deals to $50.50.

The firm delayed reporting its earnings last month when chief executive Michael Pearson returned from medical leave.

It is not the first controversy to surround the company, which is under investigation by the Securities and Exchange Commission (SEC) for pricing and supplier practices according to reports.

Valeant is expected to restate past earnings, with particular attention on specialty pharmacy Philidor Rx, which was accused of inflating its revenue figures.

Jonny.jpg


Register here to be notified of future VRX Company articles
View full VRX profile

Valeant Pharmaceuticals Timeline

Article
February 28 2017

Related Articles

Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use